Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Morris

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Chemistry & Biology|June 24, 2014
Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicityMelinda M Mulvihill, Daniel I Benjamin, Xiaodan Ji, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2019
(<i>2R,6R</i>)-hydroxynorketamine exerts mGlu<sub>2</sub> receptor-dependent antidepressant actionsPanos Zanos, Jaclyn N Highland, Brent W Stewart, et al.
European Journal of Medicinal Chemistry|December 7, 2020
<sup>18</sup>F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomographyFeng Hu, Patrick J Morris, Jordi Bonaventura, et al.
British Journal of Pharmacology|April 4, 2019
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic dosesPanos Zanos, Jaclyn N Highland, Xin Liu, et al.
ACS Chemical Neuroscience|February 3, 2022
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2<i>,</i>6)- and (5<i>R</i>)-Methyl-(2<i>R,</i>6<i>R</i>)-hydroxynorketaminesJaclyn N Highland, Patrick J Morris, Kylie M Konrath, et al.
Pharmacological Reviews|March 6, 2021
Hydroxynorketamines: Pharmacology and Potential Therapeutic ApplicationsJaclyn N Highland, Panos Zanos, Lace M Riggs, et al.
Pharmacological Reviews|June 28, 2018
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic MechanismsPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Nature|September 30, 2017
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade gliomaHumsa S Venkatesh, Lydia T Tam, Pamelyn J Woo, et al.
Molecular Psychiatry|February 23, 2022
Time will tell. Reply to "Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al." by Chen et alJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Molecular Psychiatry|June 22, 2022
The show must go on. Reply to "Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al" by Insop ShimJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Chemistry & Biology|June 24, 2014
Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicityMelinda M Mulvihill, Daniel I Benjamin, Xiaodan Ji, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2019
(<i>2R,6R</i>)-hydroxynorketamine exerts mGlu<sub>2</sub> receptor-dependent antidepressant actionsPanos Zanos, Jaclyn N Highland, Brent W Stewart, et al.
European Journal of Medicinal Chemistry|December 7, 2020
<sup>18</sup>F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomographyFeng Hu, Patrick J Morris, Jordi Bonaventura, et al.
British Journal of Pharmacology|April 4, 2019
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic dosesPanos Zanos, Jaclyn N Highland, Xin Liu, et al.
ACS Chemical Neuroscience|February 3, 2022
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2<i>,</i>6)- and (5<i>R</i>)-Methyl-(2<i>R,</i>6<i>R</i>)-hydroxynorketaminesJaclyn N Highland, Patrick J Morris, Kylie M Konrath, et al.
Pharmacological Reviews|March 6, 2021
Hydroxynorketamines: Pharmacology and Potential Therapeutic ApplicationsJaclyn N Highland, Panos Zanos, Lace M Riggs, et al.
Pharmacological Reviews|June 28, 2018
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic MechanismsPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Nature|September 30, 2017
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade gliomaHumsa S Venkatesh, Lydia T Tam, Pamelyn J Woo, et al.
Molecular Psychiatry|February 23, 2022
Time will tell. Reply to "Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al." by Chen et alJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Molecular Psychiatry|June 22, 2022
The show must go on. Reply to "Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et al" by Insop ShimJordi Bonaventura, Sherry Lam, Meghan Carlton, et al.
Pageof 5